WELLINGTON, New Zealand--(BUSINESS WIRE)--Author-it Software Corporation today announced that the pharmaceutical company Boehringer Ingelheim selected Docuvera to enable medical authors to efficiently build clinical and regulatory documents from pre-approved components of medical content. Docuvera gives Boehringer Ingelheim a powerful, yet intuitive platform for authors to create and update pharmaceutical documentation in a fraction of the time versus traditional desktop software.
Docuvera, developed specifically for the Life Sciences market, combines component authoring, review and approval, publishing, and audit trails on a single platform allowing BioPharmas to collaboratively author documents, conduct targeted reviews of modified components, and publish Word, PDF or HTML documents from a single source. And, when source content changes, modifications efficiently cascade to documents reusing component content.
“For years, BioPharmas have searched for a solution to the inefficient copying-and-pasting of documents using traditional desktop software. Unfortunately, their only option was complicated software requiring medical authors to think like software programmers,” said Paul Reid, CEO of Author-it. “With Docuvera, medical authors now have an intuitive system that feels as familiar as desktop software, but also allows them to create/update, review/approve and publish documents in a fraction of the time as traditional methods.”
Docuvera is a new breed of SaaS services targeting the Life Sciences segment bringing new technology to an industry that has traditionally been underserved by advances in software. As BioPharmas look for ways to deliver more value with existing resources, increase reliability in meeting deadlines, and improve their overall compliance footprint, Docuvera is becoming an increasingly valuable tool to improve documentation within the drug development lifecycle.
Additional Information, please contact Stephen Owens at stephen.owens@author-it.com or visit docuvera.com.
About Boehringer Ingelheim
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
About Author-it Software Corporation
Author-it Software Corporation (ASC) is a leader in structured content management software for various industries around the world. Through a variety of products and services, ASC serves more than 300 customers, ranging from the world’s largest pharmaceutical companies to emerging business in high tech manufacturing. ASC is headquartered in Wellington, NZ, with offices in North America and Europe. For more information, visit author-it.com.
